Drug Interactions with Paracetamol, Pantoprazole, and Domperidone
None of the listed medications (adalimumab, colchicine, deflazacort, apremilast, or telmisartan) have clinically significant interactions with paracetamol, pantoprazole, or domperidone that would require dose adjustments or avoidance.
Detailed Analysis by Drug
Telmisartan
No clinically significant interactions exist. FDA labeling explicitly states that co-administration of telmisartan did not result in clinically significant interactions with acetaminophen (paracetamol) 1. Telmisartan is not metabolized by cytochrome P450 enzymes and shows only minimal CYP2C19 inhibition, making interactions with pantoprazole (a CYP2C19 substrate) negligible.
Paracetamol (Acetaminophen)
Paracetamol has remarkably few clinically significant drug interactions at therapeutic doses 2. The primary concern is potentiation of hepatotoxicity in overdose situations with enzyme-inducing drugs, which does not apply to any of your listed medications. None of the drugs you've listed are enzyme inducers that would affect paracetamol metabolism.
Pantoprazole
Pantoprazole demonstrates a low potential for drug interactions compared to other proton pump inhibitors 3, 4. Studies show pantoprazole does not affect the pharmacokinetics of numerous medications including diazepam, diclofenac, digoxin, warfarin, and others 4. Neither colchicine, adalimumab, deflazacort, apremilast, nor telmisartan are substrates significantly affected by pantoprazole's minimal CYP450 effects.
Domperidone
The combination of domperidone with paracetamol has been studied directly and found to be safe, with no significant adverse events reported 5. None of your listed medications have documented interactions with domperidone.
Colchicine
While colchicine has important interactions with CYP3A4 and P-glycoprotein inhibitors [6, @1-5@], neither paracetamol, pantoprazole, nor domperidone are significant inhibitors of these pathways. The extensive literature on colchicine interactions focuses on strong CYP3A4/P-gp inhibitors (like clarithromycin, cyclosporine) and statins—none of which apply here.
Adalimumab, Deflazacort, and Apremilast
These medications lack documented interactions with paracetamol, pantoprazole, or domperidone in available literature 7, 8. As biologics (adalimumab) and immunomodulators (apremilast, deflazacort), they do not share metabolic pathways that would create interactions with these commonly used medications.
Clinical Bottom Line
All five medications can be safely co-administered with paracetamol, pantoprazole, and domperidone without dose adjustments. The only caveat is standard monitoring for each drug's individual adverse effects, but no additional monitoring is required due to drug-drug interactions with this specific combination.